Stocks
Funds
Screener
Sectors
Watchlists
LMAT

LMAT - LeMaitre Vascular Inc Stock Price, Fair Value and News

$85.07-0.26 (-0.30%)
Market Closed

52/100

LMAT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

LMAT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$80.01

Target 3M

$83.13

Target 6M

$82.11

LMAT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LMAT Price Action

Last 7 days

-2.2%

Last 30 days

2.5%

Last 90 days

-3.9%

Trailing 12 Months

-15.1%

LMAT RSI Chart

LMAT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LMAT Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

36.18

Price/Sales (Trailing)

8.01

EV/EBITDA

24.89

Price/Free Cashflow

26.34

LMAT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$80.01

Target 3M

$83.13

Target 6M

$82.11

LMAT Fundamentals

LMAT Revenue

Revenue (TTM)

240.9M

Rev. Growth (Yr)

11.36%

Rev. Growth (Qtr)

-4.96%

LMAT Earnings

Earnings (TTM)

53.3M

Earnings Growth (Yr)

55.84%

Earnings Growth (Qtr)

26%

LMAT Profitability

EBT Margin

28.61%

Return on Equity

14.08%

Return on Assets

8.92%

Free Cashflow Yield

3.8%

LMAT Investor Care

Dividend Yield

0.89%

Dividend/Share (TTM)

0.76

Shares Dilution (1Y)

0.90%

Diluted EPS (TTM)

2.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025226.3M234.6M240.9M0
2024199.9M205.6M213.0M219.9M
2023169.2M177.2M185.6M193.5M
2022158.1M159.5M160.2M161.7M
2021134.7M150.5M152.5M154.4M
2020119.3M114.7M122.0M129.4M
2019108.1M110.5M115.5M117.2M
2018102.7M104.0M103.3M105.6M
201793.0M96.4M98.0M100.9M
201679.7M82.2M86.3M89.2M
201573.3M75.0M76.5M78.4M
201465.9M68.1M70.3M71.1M
201358.2M59.8M61.4M64.5M
201257.0M56.3M55.3M56.7M
201156.8M57.8M58.7M57.7M
201000056.1M
LMAT
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
 CEO
 WEBSITElemaitre.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES591

LeMaitre Vascular Inc Frequently Asked Questions


LMAT is the stock ticker symbol of LeMaitre Vascular Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of LeMaitre Vascular Inc is 1.93 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LMAT's fair value in chart for subscribers.

The fair value guage provides a quick view whether LMAT is over valued or under valued. Whether LeMaitre Vascular Inc is cheap or expensive depends on the assumptions which impact LeMaitre Vascular Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LMAT.

As of Wed Jan 28 2026, LMAT's PE ratio (Price to Earnings) is 36.18 and Price to Sales (PS) ratio is 8.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LMAT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, LeMaitre Vascular Inc has provided 0.193 (multiply by 100 for percentage) rate of return.